EU regulators approve Pfizer antibiotic Emblaveo [Seeking Alpha]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Seeking Alpha
Pfizer said the European Commission has approved the drug for adults with complicated intra-abdominal infections, hospital-acquired pneumonia, and complicated urinary tract infections, including pyelonephritis. The EC also approved the product for the treatment of infections due to aerobic Gram-negative organisms in adults with limited options. Emblaveo is a combination of the drugs aztreonam and avibactam. The product was co-developed by AbbVie and Pfizer . AbbVie holds commercial rights to the product in the US and Canada, with Pfizer holding the remaining worldwide rights. Recommended For You More Trending News Recommended For You More Trending News Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Here's Why Pfizer (PFE) is a Strong Momentum Stock [Yahoo! Finance]Yahoo! Finance
- Advanced Drug Delivery Market Size to Surpass USD 375.86 Billion by 2033 [Yahoo! Finance]Yahoo! Finance
- Investing in Healthcare (HHL) offers value, growth Opportunities, and Income [Wealth Professional (Canada)]Wealth Professional
- NHS to provide Pfizer's Voxelotor to treat sickle cell disease [Yahoo! Finance]Yahoo! Finance
- [Latest] Global Cancer Cachexia Market Size/Share Worth USD 5.1 Billion by 2033 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) [Yahoo! Finance]Latest
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 5/1/24 - Form 4
- 5/1/24 - Form 4
- 5/1/24 - Form 8-K
- PFE's page on the SEC website